Mr. Pratap Sandhu reports

THE PRECISION PEPTIDE COMPANY ADVANCES FIRST-TO-MARKET THYMOSIN ALPHA-1 PATCH FOR IMMUNE SUPPORT

Testing is under way for The Precision Peptide Company Inc.'s Thymosin Alpha-1 transdermal patch.

Highlights:

• Q3 or Q4 2026 is the targeted completion period for testing of The Precision Peptide Company's Thymosin Alpha-1 transdermal patch.
• Research in 2025 continues to evaluate Thymosin Alpha-1 for immune regulation and inflammation, supporting its continuing relevance within the peptide and immune health landscape.
• The patch is being developed to bring Thymosin Alpha-1 into a portable, needle-free format without mixing or cold storage.
• Based on its review of currently publicly available products, The Precision Peptide Company believes the product could be among the first commercially available Thymosin Alpha-1 transdermal patches.
• Testing will evaluate formulation stability and performance within the transdermal patch format.
• The program expands the transdermal portfolio into the immune support category.

Testing is focused on formulation stability and performance within the patch format and is targeted for completion in Q3 or Q4 2026.

Based on its review of currently available products, The Precision Peptide Company believes the product could be among the first commercially available Thymosin Alpha-1 transdermal patches.

Thymosin Alpha-1 is a naturally occurring peptide that has been studied for its immune-modulating properties. A 2025 systematic review and meta-analysis examined its role in immune regulation, inflammation and infection-related outcomes, demonstrating continued scientific interest in its potential immune-related applications.

The study did not evaluate The Precision Peptide Company's patch, which remains under development and testing.

The patch is a consumer wellness product and has not been evaluated by the U.S. Food and Drug Administration or Health Canada. It is not intended to diagnose, treat, cure or prevent any disease.

Addressing the delivery gap

Thymosin Alpha-1 has traditionally been associated with injectable administration. The Precision Peptide Company is developing the transdermal patch as a portable, needle-free alternative that can be applied directly to the skin without mixing, preparation or cold storage.

The format is intended to make Thymosin Alpha-1 easier to transport and incorporate into daily wellness routines. It also supports The Precision Peptide Company's broader strategy of converting peptide ingredients into convenient, consumer-ready formats.

The company's development approach targets three key functions: stabilization of the peptide formulation, permeation through the skin and sustained release over time.

The patch is being formulated and tested in the United States, supporting The Precision Peptide Company's focus on U.S.-based product development and manufacturing.

Testing and development timeline

Current testing will evaluate whether Thymosin Alpha-1 can be maintained in a stable patch formulation and delivered consistently through the intended transdermal format.

Completion is targeted for Q3 or Q4 2026. Subject to successful testing, the product would expand The Precision Peptide Company's transdermal portfolio into the immune support category and provide another potential commercial application for its delivery platform.

Pratap Sandhu, chief executive officer of The Precision Peptide Company, commented: "Thymosin Alpha-1 has an established research history in immune regulation, but the available delivery formats have not been designed around everyday consumer convenience. We are working to change that by developing a portable, needle-free patch that requires no mixing or cold storage.

"Our immediate focus is completing formulation and stability testing in Q3/Q4 2026. Based on our review of currently available products, we believe this could be among the first commercially available Thymosin Alpha-1 transdermal patches and an important addition to our growing patch portfolio."

Expanding the transdermal portfolio

The Thymosin Alpha-1 program builds on The Precision Peptide Company's broader work in transdermal delivery and its focus on stabilization, permeation and sustained-release applications.

The patch portfolio is being developed to address recovery, immunity and other targeted wellness categories through formats intended to be simpler and more portable than conventional administration methods. The company's broader strategy centres on quality consumer-ready accessible peptide formats.

About The Precision Peptide Company Inc.

The Precision Peptide Company is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.

We seek Safe Harbor.